United Therapeutics
$541.70Change from previous close: −5.19%Absolute change: −$29.68
At a glance
- Revenue growth
- +10.61%
- 2025 vs 2024
- Net income growth
- +11.68%
- 2025 vs 2024
- Net margin
- 41.9%
- 2024: 41.5%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total revenue | 783 | 782 | 790 | 800 | 799 |
| Cost of revenue | 99.5 | 133 | 103 | 101 | 87.6 |
| Gross profit | 684 | 648 | 687 | 699 | 711 |
| Selling, general and administrative | 207 | 184 | 190 | 182 | 191 |
| Research and development | 146 | 138 | 140 | 128 | 134 |
| Operating income | 331 | 326 | 358 | 389 | 386 |
| EBIT | 376 | 321 | 447 | 441 | 416 |
| EBITDA | 400 | 344 | 470 | 463 | 437 |
| Interest expense | 2.9 | 3.0 | 3.1 | 3.0 | 7.3 |
| Pre-tax income | 373 | 318 | 444 | 438 | 408 |
| Income tax | 39.7 | 43.4 | 79.7 | 99.3 | 98.9 |
| Net income | 333 | 275 | 364 | 339 | 310 |
| Net income to common shareholders | 333 | 275 | 364 | 339 | 310 |
| Basic EPS | 7.82 | 6.32 | 8.41 | 7.73 | 6.86 |
| Diluted EPS | 7.27 | 5.82 | 7.70 | 7.16 | 6.41 |
| Average shares (basic) | 42.6 | 43.5 | 43.3 | 43.8 | 45.1 |
| Average shares (diluted) | 45.8 | 47.2 | 47.3 | 47.3 | 48.3 |